Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody-drug composite platform using bispecific antibody

A bispecific antibody, antibody drug technology, applied in the direction of antibodies, drug combinations, anti-tumor drugs, etc.

Pending Publication Date: 2019-03-01
SEOUL NAT UNIV R&DB FOUND
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a result, there are many difficulties in developing traditional ADCs using site-specific conjugation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody-drug composite platform using bispecific antibody
  • Antibody-drug composite platform using bispecific antibody
  • Antibody-drug composite platform using bispecific antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1: Cell Culture

[0050] A549 (human lung adenocarcinoma) cells were obtained from a Korean cell line bank, and supplemented with 10% heat-inactivated fetal bovine serum (GIBCO, Grand Island, NY, USA), 100 U / mL penicillin, and 100 μg / mL chain Mycin RPMI-1640 medium (Welgene, Seoul, South Korea) containing 5% CO 2 grow in a moist atmosphere. HEK293F cells (Invitrogen, Carlsbad, CA, USA) were cultured in vented Erlenmeyer tissue culture flasks (Corning Inc., NY, USA) in FreeStyle® containing 100 U / mL penicillin and 100 μg / mL streptomycin. TM In 293Expression medium (GIBCO), in a rotary shaking incubator (Minitron, INFORS HT, Bottmingen, Switzerland) at 135rpm, at 37°C, containing 7% CO 2 grow in a 70% humid atmosphere.

Embodiment 2

[0051] Example 2: Construction and purification of bispecific cetuximab × anti-cotinine antibody

[0052] In order to construct a bispecific cetuximab × anti-cotinine antibody expression vector, chemically synthesized cetuximab light chain and cetuximab heavy chain-linker (Gly-Gly-Gly-Gly-Ser ) 3 - Anti-cotinine single-chain variable fragment (scFv) gene (Genscript, Piscataway, NJ, USA). Restriction sites AgeI and XbaI were inserted at the 5' and 3' ends of the gene encoding the cetuximab light chain, respectively. Additional restriction sites NheI and BsiWI were inserted at the 5' end of the gene encoding the cetuximab heavy chain and at the 3' end of the anti-cotinine scFv gene. Light and heavy chain-linker-anti-cotinine-scFv were subcloned into mammalian expression vectors designed for secretion of recombinant proteins as described in the following methods: Park S, Lee DH, Park JG, Lee YT, Chung J. A sensitive enzyme immunoassay for measuring cotinine in passive smokers....

Embodiment 3

[0054] Embodiment 3: sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)

[0055] Analysis was performed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using NuPage 4% to 12% Bis-Tris gels (Invitrogen) according to the manufacturer's instructions. Gels were stained with Coomassie brilliant blue R-250 (Amresco, Colon, OR, USA).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an antibody-drug composite using a bispecific antibody and a use thereof. According to the antibody-drug composite of the present invention, a composite of an antibodyand a drug can be easily formed by a binding of a conjugate of a bivalent cotinine-peptide and a drug and an anti-cotinine single chain variable fragment without the need of a multi-step synthesis procedure In addition, the antibody-drug composite of the present invention can effectively deliver the drug to a target to which the antibody specifically binds, and can improve the therapeutic effectby increasing the half-life of the drug in the body.

Description

technical field [0001] The present invention relates to antibody drug conjugates using bispecific antibodies and uses thereof. [0002] Cross References to Related Applications [0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 352,804, filed June 21, 2016, the entire disclosure of which is incorporated by reference in the specification and drawings. Background technique [0004] Antibody drug conjugates (ADCs) are a new class of anticancer agents and were developed for the selective delivery of cytotoxic agents to antigen-expressing tumor cells. Traditional ADCs have high applicability and many advantages of using site-specific binding methods. However, in order to link cytotoxic agents to antibodies, multi-step conjugation methods are required, and the process of optimizing individual antibodies is required, making it difficult to use ADCs. [0005] Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/50A61K31/404A61K31/40
CPCA61K31/40A61K31/404A61K47/6897A61K47/545A61K47/555A61K47/6879A61K47/6889A61K47/65A61P35/00A61K47/6803A61K47/68033A61K47/6849A61K31/407A61K31/4188A61K2039/505C07K16/2863C07K16/468C07K2317/24C07K2317/31C07K2317/526C07K2317/56C07K2317/94
Inventor 郑埈昊陈姈金孝悧朴健佑金洙铉
Owner SEOUL NAT UNIV R&DB FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com